3B/BMC Announces Global Strategy to Invalidate ResMed Patent Portfolio

LAKE WALES, Fla. (July 28, 2014)—BMC Medical Co., Ltd and 3B Medical, Inc. (“3B/BMC”) announced today a global strategy to go on offense and seek to invalidate portions of ResMed’s patent portfolio in China, Germany and the United States. James Xu, President of BMC Medical, confirmed that challenges to a large body of patents have already been filed simultaneously in all three countries, with trials concluded in the United States and China.